ACRV
Acrivon Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$60.83M
P/E Ratio
—
EPS
$-2.02
Beta
1.74
52W High
$3.56
52W Low
$1.05
50-Day MA
$1.63
200-Day MA
$1.75
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of precision cancer medicines. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-82.76M |
| Operating Margin | 0.00% |
| Return on Equity | -53.90% |
| Return on Assets | -32.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.56 |
| Price-to-Book | 0.52 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.43 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $38.74M |
| Float | $25.67M |
| % Insiders | 6.81% |
| % Institutions | 48.05% |
Analyst Ratings
Consensus ($11.50 target)
3
Strong Buy5
Buy1
HoldData last updated: 4/7/2026